Virtus Investment Advisers’s Keros Therapeutics KROS Stock Holding History

Virtus Investment Advisers’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,676	Closed	-$140K	–	488
2026 Q1	$140K	Buy	12,676 +309	+2%	+$4.77K	0.04%	444
2025 Q4	$252K	Buy	12,367 +4,025	+48%	+$70.6K	0.07%	326
2025 Q3	$132K	Buy	8,342 +1,448	+21%	+$21.4K	0.04%	396
2025 Q2	$92K	Sell	6,894 -2,013	-23%	-$27.2K	0.03%	367
2025 Q1	$90.8K	Buy	+8,907	New	+$103K	0.02%	433
2023 Q3	–	Sell	-2,953	Closed	-$119K	–	272
2023 Q2	$119K	Sell	2,953 -5,422	-65%	-$238K	0.08%	235
2023 Q1	$358K	Buy	8,375 +262	+3%	+$13.2K	0.25%	120
2022 Q4	$390K	Hold	8,113	–	–	0.26%	121
2022 Q3	$305K	Buy	+8,113	New	+$281K	0.14%	143

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Virtus Investment Advisers's KROS Position: Q2 2026 in Review

Virtus Investment Advisers sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 12,676 shares — an estimated $140K sold.

Virtus Investment Advisers first reported a position in KROS in Q3 2022 and held it in 9 quarters. The position peaked at $390K in Q4 2022. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Virtus Investment Advisers reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtus Investment Advisers sold 12,676 Keros Therapeutics shares in Q2 2026, an estimated $140K.
Virtus Investment Advisers first reported a position in Keros Therapeutics in Q3 2022 and held it in 9 quarters.
Virtus Investment Advisers's Keros Therapeutics position peaked at $390K in Q4 2022.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.